Search company, investor...


Founded Year



Series C | Alive

Total Raised




Last Raised

$31M | 16 yrs ago

About Kemia

Kemia discovers and develops new, oral small molecule medicines for well-validated, clinically significant targets. Kemia applies proprietary chemistries and medicinal chemistry experience to two large and as yet underdeveloped classes of small molecule drug opportunities -- alpha helix interactions and allosteric kinase inhibitors. These target classes include numerous potential drug discovery targets across major disease areas including inflammation, cancer, HIV, diabetes and bone diseases.

Headquarters Location

9393 Town Ctr. Drive #200 Suite 100

San Diego, California, 92121,

United States


Missing: Kemia's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Kemia's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing Kemia

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Kemia is included in 3 Expert Collections, including Cancer.



1,179 items

Pharmaceutical and biotechnology companies with cancer therapy drug candidates.



1,903 items


Biopharma Tech

838 items

Kemia Patents

Kemia has filed 1 patent.

The 3 most popular patent topics include:

  • Commerce websites
  • Financial transaction tax
  • International taxation
patents chart

Application Date

Grant Date


Related Topics



International taxation, Financial transaction tax, Payment systems, Commerce websites, Transfer tax


Application Date


Grant Date


Related Topics

International taxation, Financial transaction tax, Payment systems, Commerce websites, Transfer tax



Latest Kemia News

Kemia Himon | McDaniel College

Mar 26, 2020

Kemia Himon has been named director of financial aid at McDaniel College. Throughout her career, she has worked in higher education financial aid departments, previously serving as the financial aid director at Arkansas Baptist College, a private, historically black liberal arts college in Little Rock, Arkansas. At McDaniel, she oversees the college’s financial aid program of federal, state and institutional aid. More than 90 percent of students at McDaniel receive some type of financial assistance, and the college invests more than $40 million annually in need-based grants and merit scholarships to ensure that students from all kinds of financial backgrounds are able to experience a McDaniel education. Under Himon’s leadership, every McDaniel student is now assigned to a specific financial aid staff member who will assist them throughout their four years at McDaniel. Information in Movers and Shakers is provided by the submitter. To submit a Movers and Shakers item, visit .

Kemia Frequently Asked Questions (FAQ)

  • When was Kemia founded?

    Kemia was founded in 2002.

  • Where is Kemia's headquarters?

    Kemia's headquarters is located at 9393 Town Ctr. Drive #200, San Diego.

  • What is Kemia's latest funding round?

    Kemia's latest funding round is Series C.

  • How much did Kemia raise?

    Kemia raised a total of $83.5M.

  • Who are the investors of Kemia?

    Investors of Kemia include Texas Pacific Group, Alta Partners, Forward Ventures, Novartis Venture Funds, J.P. Morgan & Co. and 8 more.

  • Who are Kemia's competitors?

    Competitors of Kemia include Oligomerix, Elusys Therapeutics, Ocera Therapeutics, Threshold Pharmaceuticals, Probiodrug and 11 more.

Compare Kemia to Competitors

Bikam Pharmaceuticals

BIKAM Pharmaceuticals, Inc. is an early stage biopharmaceutical company focusing upon the discovery and development of small molecule therapeutics for the treatment of ophthalmic diseases and disorders, including retinitis pigmentosa. Worldwide, there are approximately 1.5 million people which suffer from retinitis pigmentosa (RP), a hereditary disease which leads to blindness. As its initial priority, the company is pursuing the discovery of compounds based on a novel mechanism of action identified by the company's founder, Dr. Shalesh Kaushal. BIKAM has an experienced management team with a strong track record in pharmaceutical drug discovery dedicated to expanding these findings and others from the Kaushal lab to create potential therapeutics to prevent blindness.


BrainCells is a biopharmaceutical company focused on the development of small molecule therapeutics for diseases of the central nervous system (CNS). The company's technology platform is based on research in the field of neurogenesis and recent discoveries linking neurogenesis to CNS disease states. BCI is using its neurogenesis technology platform to identify clinical-stage compounds, targets and compounds optimal for CNS indications. BCI is building a pipeline of clinical-stage programs to address unmet medical needs in the treatment of mood disorders, psychoses, cognition, brain repair syndromes and other CNS disorders.

Sonexa Therapeutics

Sonexa Therapeutics is a clinical-stage biopharmaceutical company developing therapeutics for the treatment of Alzheimer's disease. ST101, the company's lead compound, represents an agent that, in animal models, has demonstrated both the cognitive benefits of currently marketed AD treatments along with significant disease modifying effects. ST101 has completed Phase I studies in both healthy volunteers and AD patients. It is being evaluated in Phase II Proof-of-Concept trials.

Selectx Pharmaceuticals

SelectX Pharmaceuticals is a biopharmaceutical company that focuses on the discovery and development of small molecule antimicrobials and other therapeutics for unmet medical needs through the application of its Genetic Chemistry platform.

Oligomerix Logo

Oligomerix is a clinical-stage biotechnology company. It focuses on developing disease-modifying therapeutics for neurodegenerative diseases characterized by the aberrant tau protein, ranging from tauopathies such as progressive supranuclear palsy and frontotemporal dementia to Alzheimer’s disease. The firm serves clients in the healthcare sector. Oligomerix was founded in 2006 and is based in West Harrison, New York.

Longevica Logo

Longevica is a biotechnology that is researching mechanisms of healthy aging and life extension. The company is also developing an open research tool for scientists and research institutions to access a data set that tracks the effects of pharmacological compounds for testing drugs.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.